peppersite
Metabolic supportsubcutaneous

Retatrutide

Retatrutide is an investigational once-weekly injectable that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is being studied for weight and metabolic outcomes in adults with obesity, type 2 diabetes and fatty liver disease.

Researched for
Metabolic HealthBody CompositionWeight ManagementAppetite Regulation

At a glance

Also called
RT3
Type
Metabolic support
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it human data available
Reported amount
1 mg per Peptide Dosing Protocols. All 4 sources
Typical vial
10 mg in 2 mL

How much to draw

Full calculator →
Your draw
20units
0.2 mL on a U-100 insulin syringe
5 mg/mL10 doses per vial
Amount per dose

Opened on 1 mg, the figure Peptide Dosing Protocols reports for Retatrutide, and a 10 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Retatrutide or for anything else, and nothing below has been checked against the study it came from.

Standard: 1 mg once weekly · Low: 1 mg · High: 12 mg
Frequency
once per weeknull · null
Route
Subcutaneous injection
Reported by
Peptide Dosing Protocols
What it saysThe standard dosing starts at 1 mg once weekly and titrates up to 12 mg.
0.5 mg starting dose, escalating to target of 8-12 mg
Frequency
Once weeklyKey Question
Route
subcutaneous or oral
Reported by
Peptide Protocol Wiki
Standard: 1 mg titrating to 12 mg once weekly (Phase 3 TRIUMPH: 1 mg → 2 mg → 4 mg → 6 mg → 9 mg → 12 mg, stepping up every 4 weeks) · Low: 1 mg once weekly · High: 12 mg once weekly
Frequency
Once per week, on the same day each week48 weeks (Phase 2 reference); 68-72 weeks (Phase 3 TRIUMPH reference) · Every 4 weeks at each dose step; review at 4 mg, 9 mg, 12 mg; slow titration option adds 2-4 weeks per dose step when GI symptoms persist
Route
Subcutaneous injection
Reported by
Peptide Dosing Protocols
What it saysRetatrutide is dosed once weekly via subcutaneous injection starting at 1 mg and titrating up every 4 weeks to a maximum of 12 mg following the Phase 3 TRIUMPH schedule.
1-12 mg
Frequency
Once weekly · Any time of dayTitrate over weeks per response/tolerance
Route
subcutaneous
Reported by
Reference titration range, provider confirm
Reconstitution, as reported
  • null
  • 10 mg vial with 2.0 mL BAC water yields a concentration of 5 mg/mL; use U-100 insulin syringes
What our audits found

How it is thought to work

Acting on three pathways together, it appears to reduce appetite, improve blood sugar handling and raise the rate at which the body burns calories. Researchers attribute the weekly interval to a half-life of roughly six days, created by a fatty diacid attachment that binds the peptide to albumin in the blood. The glucagon part is thought to add energy expenditure and fat burning beyond what GLP-1 and GIP give on their own. Retatrutide is investigational and not FDA-approved, and the Phase 3 results reported so far are topline only.

In technical termsTriple agonism of GLP-1, GIP, and glucagon receptors; studied for appetite regulation and energy expenditure.

What we don't know

Full Phase 3 results: the Phase 3 figures reported so far are topline. The reference entry says full peer-reviewed TRIUMPH-1 data had not been published as of June 2026, and more readouts were expected through 2026 and 2027.

Conference results: detailed results from the type 2 diabetes trial were scheduled for the American Diabetes Association Scientific Sessions in June 2026. The outcome is not recorded here.

Safety and effect size: our audit notes that the drug is still in Phase 3 because the full answer on safety and effect size is not yet known. It has not been studied in pregnant or breastfeeding people.

Reported side effects

Seen in studies: in the Phase 2 trial, the highest arm reported vomiting in up to 26 percent of participants, nausea in up to 25 percent, diarrhoea in up to 23 percent and constipation in up to 16 percent, mostly mild to moderate and concentrated while the amount was being raised. A Phase 3 readout reported dysesthesia, meaning unusual skin sensitivity, tingling or tenderness to touch, in about 20.9 percent of participants in the highest arm, described as the clearest signal separating retatrutide from older GLP-1 compounds. Resting heart rate rose by roughly 5 to 10 beats per minute on average, peaking near week 24 and easing by weeks 36 to 48, with no increase in serious cardiovascular events in Phase 2. Temporary rises in liver enzymes occurred in a minority, injection-site reactions in roughly 5 to 15 percent, and 6 to 16 percent of Phase 2 participants stopped because of side effects, against none on placebo.

Not ruled out: research-grade material is not standardised for human use, and poor handling or contaminated water can cause injection-site problems that resemble side effects.

Who should avoid it

People with a history of pancreatitis or gallbladder disease: excluded from the trials because of the known association between this class of compound and pancreatic and biliary risk.

People with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia type 2: excluded, mirroring the class-wide concern about thyroid C-cell tumours.

People with severe gastroparesis: excluded, since GLP-1 activity slows the gut further.

People with recent major cardiovascular events, severe kidney impairment or severe liver disease: excluded from trials or flagged as needing clinician oversight.

People with type 1 diabetes: excluded from the obesity studies.

People with diabetic retinopathy or active retinal disease, or with severe gut conditions such as an inflammatory bowel disease flare: flagged as needing clinician oversight.

People taking insulin or sulfonylureas: flagged as needing clinician oversight because of the risk of low blood sugar.

People who are pregnant, breastfeeding or trying to conceive: retatrutide has not been studied in them, and the trials required effective contraception.

What gets monitored

Weight/body-composition trend, glucose/HbA1c, GI tolerance, heart rate per provider.

Regulatory status

FDA approval: retatrutide is investigational and was not FDA-approved as of June 2026. Our audit from August 2026 says no regulator anywhere has approved it and that Eli Lilly did not plan to submit an FDA application until the following year. Analyst projections of approval in late 2027 or 2028 are estimates, not decisions.

Compounding: the audit reports the FDA's position as being that selling unapproved retatrutide to consumers is illegal and that it cannot lawfully be compounded.

Lawsuits: on August 12, 2026 Eli Lilly filed six suits against six sellers. Lilly alleges they sold black market retatrutide and that some marketed it as for research use only when it was meant for people to inject. These are allegations, and the audit says nobody has been found liable. A follow-up audit says we could not obtain the complaints, so the exact legal claims are not confirmed. The outcome of the suits is not recorded here.

Checked: November 2026.

Common questions

What amounts of retatrutide are used in trials?

Reported amounts and schedules for retatrutide differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What is the half-life of retatrutide?

Retatrutide's half-life is about six days, which is the stated basis for once-weekly injection. After stopping, clearance takes roughly five half-lives, around 30 days. The long half-life comes from a fatty diacid attachment that binds the peptide to albumin.

How much weight loss does retatrutide produce in trials?

In the Phase 2 trial, the highest arm averaged 24.2 percent body weight loss at 48 weeks. Phase 3 topline results reported 28.7 percent at 68 weeks in one trial and 28.3 percent at 80 weeks in another, with a higher-BMI subgroup reaching 30.3 percent at 104 weeks. In adults with type 2 diabetes, the highest arm averaged 16.8 percent over 40 weeks.

How do you reconstitute retatrutide?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

Is retatrutide FDA approved?

No. As of June 2026 retatrutide is investigational and still in Phase 3 trials, and Eli Lilly has not submitted a New Drug Application. Analyst projections of approval in late 2027 or 2028 are estimates, not decisions.

What are the most common side effects of retatrutide?

The most common are gut effects: nausea, diarrhoea, vomiting and constipation, concentrated while the amount is being raised. In one Phase 3 trial, about 20.9 percent of participants in the highest arm reported dysesthesia, meaning unusual skin sensitivity or tingling. Resting heart rate rose by about 5 to 10 beats per minute on average and eased over time.

How does retatrutide compare to tirzepatide and semaglutide?

Retatrutide acts on three receptors (GLP-1, GIP and glucagon), tirzepatide on two (GLP-1 and GIP) and semaglutide on one (GLP-1). Retatrutide has shown the largest weight-loss figures so far, 28.7 percent in one Phase 3 trial against 22.5 percent for tirzepatide in SURMOUNT-1 and 15.8 percent for semaglutide in STEP-1. It remains investigational.

Sources

  1. 01Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine (2023)
  2. 02Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet (2023)
  3. 03Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine (2024)
  4. 04Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism (2022)
  5. 05Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. PR Newswire / Eli Lilly press release (TRIUMPH-4 topline) (2025)
  6. 06Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. PR Newswire / Eli Lilly press release (TRIUMPH-1 topline) (2026)
  7. 07Eli Lilly and Company. Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. PR Newswire / Eli Lilly press release (TRANSCEND-T2D-1 topline) (2026)
  8. 08Eli Lilly and Company. What to know about retatrutide. Lilly.com (2026)
  9. 09ClinicalTrials.gov. TRANSCEND-T2D-1: A Study of Retatrutide (LY3437943) in Adult Participants With Type 2 Diabetes (NCT06354660). ClinicalTrials.gov (2026)
  10. 10ClinicalTrials.gov. TRIUMPH-4: A Study of Retatrutide (LY3437943) in Participants With Obesity and Knee Osteoarthritis (NCT05929066). ClinicalTrials.gov (2025)
  11. 11Tucker ME. Triple Agonist Retatrutide Reduces A1c, Weight in T2D. Medscape (2026)
  12. 12U.S. Food and Drug Administration. Statement on FDA's review of compounded versions of brand-name GLP-1 drugs and reports of online sellers marketing unapproved peptides. FDA.gov consumer guidance (2025)

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Cagrilintide / Retatrutide

Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.

Cagrilintide / Tirzepatide

Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.

CagriSema

CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.

Mazdutide

Mazdutide, also called IBI362, is an investigational lab-made peptide drug that switches on two metabolic hormone receptors at once. It is being studied in clinical trials as a once-weekly injection for weight management and metabolic health.

Semaglutide

Semaglutide is a lab-made copy of GLP-1, a gut hormone that helps the body manage hunger and blood sugar. It is among the most heavily studied weight-loss and diabetes medicines, with trial programmes covering more than 45,000 participants.

Tirzepatide

Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.